{"DataElement":{"publicId":"7533480","version":"1","preferredName":"Primary Immune Regulatory Disorder Description Name","preferredDefinition":"Text term to describe the primary immune regulatory disorder.","longName":"PIRD_NM","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"7533465","version":"1","preferredName":"Primary Immune Regulatory Disorder Description","preferredDefinition":"A group of immune diseases characterized predominantly by immune dysregulation leading to organ-specific autoimmunity, excessive inflammation, and non-malignant lymphoproliferation. Unlike classical primary immunodeficiencies, susceptibility to infections is typically less prominent in these disorders._A written or verbal account, representation, statement, or explanation of something.","longName":"7533463v1.0:2222846v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"7533463","version":"1","preferredName":"Primary Immune Regulatory Disorder","preferredDefinition":"A group of immune diseases characterized predominantly by immune dysregulation leading to organ-specific autoimmunity, excessive inflammation, and non-malignant lymphoproliferation. Unlike classical primary immunodeficiencies, susceptibility to infections is typically less prominent in these disorders.","longName":"C176600","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Immune Regulatory Disorder","conceptCode":"C176600","definition":"A group of immune diseases characterized predominantly by immune dysregulation leading to organ-specific autoimmunity, excessive inflammation, and non-malignant lymphoproliferation. Unlike classical primary immunodeficiencies, susceptibility to infections is typically less prominent in these disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6847A81-C21F-6ECB-E053-4EBD850A1D49","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2222846","version":"1","preferredName":"Description","preferredDefinition":"A statement or an account describing something.","longName":"C25365","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6211337-E099-4E34-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER_EVS","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6847A81-C22D-6ECB-E053-4EBD850A1D49","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"COOPERM","dateModified":"2020-12-23","changeDescription":"2020-12-15 AK Created for NCI-INC0536652 - 20C0070 Curation and import 11.10.2020","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7533467","version":"1","preferredName":"Primary Immune Regulatory Disorder Name","preferredDefinition":"A group of immune diseases characterized predominantly by immune dysregulation leading to organ-specific autoimmunity, excessive inflammation, and non-malignant lymphoproliferation. Unlike classical primary immunodeficiencies, susceptibility to infections is typically less prominent in these disorders._The words or language units by which a thing is known.","longName":"PIRD_NAME","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B684188F-BCDA-6DBC-E053-4EBD850A5A3A","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"HLH","valueDescription":"Hemophagocytic Lymphohistiocytosis","ValueMeaning":{"publicId":"3211128","version":"1","preferredName":"Hemophagocytic Lymphohistiocytosis","longName":"3211128","preferredDefinition":"A rare but potentially life-threatening disorder characterized by the proliferation of histiocytes and macrophages and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary, due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophagocytic Lymphohistiocytosis","conceptCode":"C34792","definition":"A rare, but potentially life-threatening disorder, characterized by the proliferation of histiocytes and macrophages, and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D1E6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B684188F-BCE4-6DBC-E053-4EBD850A5A3A","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"Cytokine/Regulatory Proteins","valueDescription":"Cytokine Immunoprotein","ValueMeaning":{"publicId":"7533468","version":"1","preferredName":"Cytokine Immunoprotein","longName":"7533468","preferredDefinition":"A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands.: A protein whose activities affect or play a role in immune system functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytokine","conceptCode":"C20464","definition":"A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunoprotein","conceptCode":"C16725","definition":"A protein whose activities affect or play a role in immune system functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B684188F-BCEE-6DBC-E053-4EBD850A5A3A","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"KUMMEROA","dateModified":"2021-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B684188F-BD07-6DBC-E053-4EBD850A5A3A","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"Transcriptional Regulators","valueDescription":"Transcription Regulatory Protein","ValueMeaning":{"publicId":"7533469","version":"1","preferredName":"Transcription Regulatory Protein","longName":"7533469","preferredDefinition":"A protein that is involved in the regulation of transcription.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transcription Regulatory Protein","conceptCode":"C26199","definition":"A protein that is involved in the regulation of transcription.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B684188F-BD11-6DBC-E053-4EBD850A5A3A","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"KUMMEROA","dateModified":"2021-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B684188F-BD2A-6DBC-E053-4EBD850A5A3A","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"JAK/STAT","valueDescription":"Jak-STAT Signaling Pathway","ValueMeaning":{"publicId":"7533470","version":"1","preferredName":"Jak-STAT Signaling Pathway","longName":"7533470","preferredDefinition":"The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies.  In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Jak-STAT Signaling Pathway","conceptCode":"C91519","definition":"The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies.  In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B684188F-BD34-6DBC-E053-4EBD850A5A3A","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"KUMMEROA","dateModified":"2021-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B684188F-BD4D-6DBC-E053-4EBD850A5A3A","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"PI3 Kinase","valueDescription":"Phosphatidylinositol 3 Kinase","ValueMeaning":{"publicId":"3412291","version":"1","preferredName":"Phosphatidylinositol 3 Kinase","longName":"3412291","preferredDefinition":"An enzyme that catalyzes the conversion of phosphatidylinositol to phosphatidylinositol 3-phosphate. This is the first committed step in the biosynthesis of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate. This pathway is thought to play a critical role in DNA repair, V(D)J recombination and cell cycle checkpoints. (from LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase","conceptCode":"C17270","definition":"An enzyme that catalyzes the conversion of phosphatidylinositol to phosphatidylinositol 3-phosphate. This is the first committed step in the biosynthesis of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate. This pathway is thought to play a critical role in DNA repair, V(D)J recombination and cell cycle checkpoints. (from LocusLink)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD48B15-35E7-4589-E040-BB89AD435660","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-09","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B684188F-BD61-6DBC-E053-4EBD850A5A3A","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"EBV Susceptibility","valueDescription":"EBV Susceptibility","ValueMeaning":{"publicId":"7533471","version":"1","preferredName":"EBV Susceptibility","longName":"7533471","preferredDefinition":"An immune system finding indicating that an individual has a likelihood for developing Epstein Barr virus infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EBV Susceptibility","conceptCode":"C176692","definition":"An immune system finding indicating that an individual has a likelihood for developing Epstein Barr virus infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B684188F-BD6C-6DBC-E053-4EBD850A5A3A","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"KUMMEROA","dateModified":"2021-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B684188F-BD85-6DBC-E053-4EBD850A5A3A","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"NFkB signaling","valueDescription":"NFkB signaling","ValueMeaning":{"publicId":"7533597","version":"1","preferredName":"NFkB signaling","longName":"7533597","preferredDefinition":"Nuclear factor kB (NF-kB) is a nuclear transcription factor that regulates expression of a large number of genes that are critical for the regulation of apoptosis, viral replication, tumorigenesis, inflammation, and various autoimmune diseases. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NFKB Signaling Pathway","conceptCode":"C39163","definition":"Nuclear factor kB (NF-kB) is a nuclear transcription factor that regulates expression of a large number of genes that are critical for the regulation of apoptosis, viral replication, tumorigenesis, inflammation, and various autoimmune diseases. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6950943-D401-48F2-E053-4EBD850A7676","latestVersionIndicator":"Yes","beginDate":"2020-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-16","modifiedBy":"COOPERM","dateModified":"2020-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6950943-D41A-48F2-E053-4EBD850A7676","beginDate":"2020-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-16","modifiedBy":"ONEDATA","dateModified":"2020-12-16","deletedIndicator":"No"},{"value":"Lymphoproliferative disorder","valueDescription":"Lymphoproliferative Disorder","ValueMeaning":{"publicId":"3235573","version":"1","preferredName":"Lymphoproliferative Disorder","longName":"3235573","preferredDefinition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoproliferative Disorder","conceptCode":"C9308","definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A366F43E-37D9-9973-E040-BB89AD43108C","latestVersionIndicator":"Yes","beginDate":"2011-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B68876B2-A21E-36F3-E053-4EBD850A0A1E","beginDate":"2020-12-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"Eczema","valueDescription":"Eczema","ValueMeaning":{"publicId":"3252129","version":"1","preferredName":"Eczema","longName":"3252129","preferredDefinition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eczema","conceptCode":"C3001","definition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A781D14A-E852-8A44-E040-BB89AD4310FD","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"COOPERM","dateModified":"2020-10-16","changeDescription":"10.16.20 Updated definition with current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B68876B2-A228-36F3-E053-4EBD850A0A1E","beginDate":"2020-12-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"Asthma","valueDescription":"Asthma","ValueMeaning":{"publicId":"2975594","version":"1","preferredName":"Asthma","longName":"2975594","preferredDefinition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asthma","conceptCode":"C28397","definition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C08420A-B206-2A47-E040-BB89AD433D97","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B68876B2-A233-36F3-E053-4EBD850A0A1E","beginDate":"2020-12-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"Allergic rhinitis","valueDescription":"Allergic Rhinitis","ValueMeaning":{"publicId":"2946541","version":"1","preferredName":"Allergic Rhinitis","longName":"2946541","preferredDefinition":"Inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea, and itching. It may lead to fatigue, drowsiness, and malaise thus causing impairment of the quality of life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allergic Rhinitis","conceptCode":"C79532","definition":"Inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea, and itching. It may lead to fatigue, drowsiness, and malaise thus causing impairment of the quality of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74A40B1A-E6AF-30F2-E040-BB89AD4307C8","latestVersionIndicator":"Yes","beginDate":"2009-09-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B68876B2-A23D-36F3-E053-4EBD850A0A1E","beginDate":"2020-12-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"Granuloma","valueDescription":"Granuloma","ValueMeaning":{"publicId":"5021905","version":"1","preferredName":"Granuloma","longName":"5021905","preferredDefinition":"An inflammatory reaction usually caused by infectious organisms, foreign bodies, or cholesterol deposits. It is characterized by the presence of epithelioid histiocytes and chronic inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granuloma","conceptCode":"C3064","definition":"An inflammatory reaction usually caused by infectious organisms, foreign bodies, or cholesterol deposits. It is characterized by the presence of epithelioid histiocytes and chronic inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2047C974-49D9-BBB9-E050-BB89AD4355F1","latestVersionIndicator":"Yes","beginDate":"2015-09-21","endDate":null,"createdBy":"SORENSENS","dateCreated":"2015-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAFDB341-3EFC-3373-E053-4EBD850A09AA","beginDate":"2021-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-02-10","modifiedBy":"ONEDATA","dateModified":"2021-02-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7533466","version":"1","preferredName":"Primary Immune Regulatory Disorder Name","preferredDefinition":"A group of immune diseases characterized predominantly by immune dysregulation leading to organ-specific autoimmunity, excessive inflammation, and non-malignant lymphoproliferation. Unlike classical primary immunodeficiencies, susceptibility to infections is typically less prominent in these disorders.:The words or language units by which a thing is known.","longName":"C176600:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Immune Regulatory Disorder","conceptCode":"C176600","definition":"A group of immune diseases characterized predominantly by immune dysregulation leading to organ-specific autoimmunity, excessive inflammation, and non-malignant lymphoproliferation. Unlike classical primary immunodeficiencies, susceptibility to infections is typically less prominent in these disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B684188F-BCB4-6DBC-E053-4EBD850A5A3A","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B684188F-BCC5-6DBC-E053-4EBD850A5A3A","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"COOPERM","dateModified":"2021-02-10","changeDescription":"2021-1-14 ak Added missing PV concepts. 2020-12-15 AK Created for NCI-INC0536652 - 20C0070 Curation and import 11.10.2020","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"PIRD","type":"Preferred Question Text","description":"PIRD","url":null,"context":"CCR"},{"name":"Immune Dysregulation Disorders","type":"Alternate Question Text","description":"Immune Dysregulation Disorders","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B684A897-C943-6B77-E053-4EBD850ADE0E","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-12-15","modifiedBy":"COOPERM","dateModified":"2020-12-23","changeDescription":"Approved for import and released. mc 12.23.2020; 2020-12-15 AK Created for NCI-INC0536652 - 20C0070 Curation and import 11.10.2020","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}